JP2024515545A5 - - Google Patents
Info
- Publication number
- JP2024515545A5 JP2024515545A5 JP2023561276A JP2023561276A JP2024515545A5 JP 2024515545 A5 JP2024515545 A5 JP 2024515545A5 JP 2023561276 A JP2023561276 A JP 2023561276A JP 2023561276 A JP2023561276 A JP 2023561276A JP 2024515545 A5 JP2024515545 A5 JP 2024515545A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- piperidine
- oxoisoindorin
- dione
- pyridine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163170865P | 2021-04-05 | 2021-04-05 | |
| US63/170,865 | 2021-04-05 | ||
| US202163189318P | 2021-05-17 | 2021-05-17 | |
| US63/189,318 | 2021-05-17 | ||
| PCT/US2022/023236 WO2022216573A1 (en) | 2021-04-05 | 2022-04-04 | Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024515545A JP2024515545A (ja) | 2024-04-10 |
| JP2024515545A5 true JP2024515545A5 (enExample) | 2025-04-04 |
| JP7892685B2 JP7892685B2 (ja) | 2026-07-21 |
Family
ID=83546459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023561276A Active JP7892685B2 (ja) | 2021-04-05 | 2022-04-04 | がん治療のためのピリジニル置換オキソイソインドリン化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250346574A1 (enExample) |
| EP (1) | EP4320125A1 (enExample) |
| JP (1) | JP7892685B2 (enExample) |
| KR (1) | KR20230167067A (enExample) |
| AU (1) | AU2022253450A1 (enExample) |
| BR (1) | BR112023020410A2 (enExample) |
| CA (1) | CA3214240A1 (enExample) |
| IL (1) | IL307338A (enExample) |
| MX (1) | MX2023011408A (enExample) |
| WO (1) | WO2022216573A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120677149A (zh) * | 2023-02-08 | 2025-09-19 | 细胞基因公司 | 用于选择性降解工程化蛋白的化合物和组合物 |
| EP4724149A1 (en) | 2023-06-07 | 2026-04-15 | Bristol-Myers Squibb Company | Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound |
| KR20260028777A (ko) | 2023-06-23 | 2026-03-04 | 브리스톨-마이어스 스큅 컴퍼니 | 항암제로서의 치환된 옥소이소인돌리닐 피페리딘-2,6-디온 화합물 |
| EP4784572A1 (en) | 2023-09-02 | 2026-08-05 | Bristol-Myers Squibb Company | Substituted azetidinyl oxoisoindolinyl piperidine-2,6-dione compounds |
| WO2025226767A1 (en) | 2024-04-24 | 2025-10-30 | Bristol-Myers Squibb Company | Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer |
| WO2026035999A1 (en) | 2024-08-09 | 2026-02-12 | Triana Biomedicines, Inc. | Anaplastic lymphoma kinase (alk) degraders and uses thereof |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| JP5238936B2 (ja) | 2005-03-25 | 2013-07-17 | ジーアイティーアール，インク． | Ｇｉｔｒ結合分子およびその使用 |
| DK1879573T3 (da) | 2005-05-10 | 2013-02-25 | Incyte Corp | Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| ES2540561T3 (es) | 2005-12-20 | 2015-07-10 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| CA2663057C (en) | 2006-09-19 | 2015-12-08 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| PT2175884T (pt) | 2007-07-12 | 2016-09-21 | Gitr Inc | Terapias de combinação empregando moléculas de ligação a gitr |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| WO2009073620A2 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics | Ido inhibitors |
| EP2296789A1 (fr) | 2008-05-29 | 2011-03-23 | Saint-Gobain Centre de Recherches et d'Etudes Européen | Structure en nid d'abeille a base de titanate d'aluminium |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| IN2015DN02826A (enExample) | 2009-09-03 | 2015-09-11 | Merck Sharp & Dohme | |
| EP2493862B1 (en) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
| DK2510010T3 (en) | 2009-12-10 | 2015-12-14 | Hoffmann La Roche | Antibodies that bind to human CSF1R extracellular domain 4 and their use |
| DK2542256T3 (da) | 2010-03-04 | 2019-08-26 | Macrogenics Inc | Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf |
| CN102918061B (zh) | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
| RU2617971C2 (ru) | 2010-03-05 | 2017-04-28 | Ф.Хоффманн-Ля Рош Аг | Антитела против csf-1r человека и их применение |
| EP3943154A1 (en) | 2010-05-04 | 2022-01-26 | Five Prime Therapeutics, Inc. | Antibodies that bind csf1r |
| NZ729044A (en) | 2010-09-09 | 2020-07-31 | Pfizer | 4-1bb binding molecules |
| NO2694640T3 (enExample) | 2011-04-15 | 2018-03-17 | ||
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| MX356337B (es) | 2011-12-15 | 2018-05-23 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
| MX2014008961A (es) | 2012-02-06 | 2014-10-14 | Genentech Inc | Composiciones y metodos para utilizar inhibidores de csf1r. |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| KR20150018533A (ko) | 2012-05-11 | 2015-02-23 | 파이브 프라임 테라퓨틱스, 인크. | 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법 |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| IL266842B (en) | 2016-12-01 | 2022-09-01 | Arvinas Operations Inc | History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists |
| AU2018300150A1 (en) | 2017-07-11 | 2020-01-30 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| CN111902141A (zh) * | 2018-03-26 | 2020-11-06 | C4医药公司 | 用于ikaros降解的羟脑苷脂结合剂 |
| EP3924054B1 (en) * | 2019-02-15 | 2025-04-02 | Novartis AG | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| CA3123519A1 (en) * | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| CN114502543A (zh) * | 2019-05-24 | 2022-05-13 | 拜欧斯瑞克斯公司 | 靶向蛋白化合物、其药物组合物及治疗应用 |
| JP7629459B2 (ja) * | 2019-11-19 | 2025-02-13 | ブリストル－マイヤーズ スクイブ カンパニー | Ｈｅｌｉｏｓタンパク質の阻害剤として有用な化合物 |
| EP4188549A1 (en) * | 2020-08-03 | 2023-06-07 | Novartis AG | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
-
2022
- 2022-04-04 EP EP22719432.1A patent/EP4320125A1/en active Pending
- 2022-04-04 IL IL307338A patent/IL307338A/en unknown
- 2022-04-04 US US18/553,999 patent/US20250346574A1/en active Pending
- 2022-04-04 WO PCT/US2022/023236 patent/WO2022216573A1/en not_active Ceased
- 2022-04-04 MX MX2023011408A patent/MX2023011408A/es unknown
- 2022-04-04 JP JP2023561276A patent/JP7892685B2/ja active Active
- 2022-04-04 KR KR1020237037710A patent/KR20230167067A/ko active Pending
- 2022-04-04 AU AU2022253450A patent/AU2022253450A1/en active Pending
- 2022-04-04 CA CA3214240A patent/CA3214240A1/en active Pending
- 2022-04-04 BR BR112023020410A patent/BR112023020410A2/pt unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2548532T3 (es) | Compuestos de pirrolopirimidina como inhibidores de CDK4/6 | |
| JP2022504936A5 (enExample) | ||
| TWI874541B (zh) | Egfr抑制劑 | |
| JP6895439B2 (ja) | ＩＲＡＫ４調節因子としてのピラゾロ［１，５ａ］ピリミジン誘導体 | |
| JP7344125B2 (ja) | 細菌感染の治療及び予防のための新規ピリド［２，３－ｂ］インドール化合物 | |
| BR112021001292A2 (pt) | compostos heterobicíclicos para inibir a atividade de shp2 | |
| JP2014506929A5 (enExample) | ||
| CA2629777A1 (en) | Spirocyclic compounds as hdac inhibitors | |
| RU2020129785A (ru) | Фармацевтические производные 6,5-гетеробициклического кольца | |
| JP2018530557A5 (enExample) | ||
| RU2016135637A (ru) | 6-гетероарилокси- и 6-арилоксихинолин-2-карбоксамиды и их применение | |
| JP2017531672A5 (enExample) | ||
| TW202246266A (zh) | 作為parp7抑制劑的三環衍生物 | |
| EP4419529A1 (en) | Covalent egfr inhibitors and methods of use thereof | |
| WO2024254532A1 (en) | Bifunctional azines conjogates as selective degraders of smarca2 and therapeutic uses thereof | |
| RU2780532C1 (ru) | Ингибиторы протеинтирозинфосфатазы | |
| US20260035387A1 (en) | Compounds for treating huntington's disease | |
| AU2023336560A1 (en) | Heterocyclic derivatives as janus kinase inhibitors | |
| TH2401004994A (th) | อิมิดาโซลมาโครไซเคิลสำหรับการบำบัดของโรคภูมิต้านต่อตนเอง | |
| JP2023549123A5 (enExample) | ||
| HUE025203T2 (en) | CDK4 / 6 inhibitor pyrrolopyrimidine compounds | |
| TH74460A (th) | อนุพันธ์ของ 8'-พิริ(มิ)ดินิล-ไดไฮโดรสไปโร-[ไซโคลอัลคิลามีน]-พิริมิโด[1,2-a]พิริมิดิน-6-โอน ที่ถูกแทนที่ |